Roivant Sciences Ltd. (ROIV) SEC Filings & Earnings Calls
EquiReason read 20 Roivant Sciences Ltd. SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Roivant announces positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis: met primary endpoint (time to treatment failure, p<0.0001) and all key secondary endp.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 26.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Oct 20268-K · 7.01Roivant announces positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis: met primary endpoint (time to treatment failure, p<0.0001) and all key secondary endpoints with high statistical significance. Median time to faiopen
Figures in the filing · each found in the filing text
| Steroid-free quiescence at Week 48 (pooled) · CLARITY pooled · Week 48 | 62.0% | |
| Median time to treatment failure · CLARITY pooled · Week 48 | $48.00 | +300% y/y |
| Resolution of macular edema at Week 48 (pooled) · CLARITY pooled · Week 48 | 42.0% | |
| Hazard ratio for treatment failure (CLARITY-1) · CLARITY-1 · Week 48 | $0.27 | |
| Hazard ratio for treatment failure (CLARITY-2) · CLARITY-2 · Week 48 | $0.22 |
Risks flagged
Regulatory and commercial risks remain; sNDA filing planned H1 2027.
“Priovant intends to file a supplemental New Drug Application (sNDA) for brepocitinib for the treatment of NIU in the first half of calendar year 2027.” · word for word
5 Oct 2026SC 13D/ARoivant Sciences maintains 19.5% passive stake in Arbutus Biopharma after participating in a tender offer to keep proportionate ownership.open
Figures in the filing · each found in the filing text
| common_outstanding_shares · 2026-10-01 | 153,275,907 | |
| beneficial_ownership_percent · 2026-10-01 | 19.5% |
8 Sep 20268-K · 7.01Roivant announced positive Phase 2 PHocus trial results for mosliciguat in PH-ILD: met primary endpoint with -56.3% PVR reduction (p<0.0001), highest ever in any PH trial; secondary endpoints also met.open
Figures in the filing · each found in the filing text
| PVR Reduction · Week 16 | 56.3% | |
| 6MWD Improvement · Week 16 | $35.20 | |
| NT-proBNP Reduction · Week 16 | 53.2% | |
| 6MWD Improvement Week 24 · Week 24 | $52.70 | |
| NT-proBNP Reduction Week 24 · Week 24 | 75.9% |
28 Aug 20268-K · 8.01FDA approval of LISRAYA (brepocitinib) for dermatomyositis. Wholesale acquisition cost $35,000 per 30-count bottle of 30 mg tablets.open
Figures in the filing · each found in the filing text
| wholesale acquisition cost · point_in_time | $35000.00 |
Risks flagged
Commercial success depends on market adoption and reimbursement
“New drug launch; pricing at $35,000 per bottle”
6 Aug 20268-K · 2.02Cash, cash equivalents, restricted cash and marketable securities $3.90B; Research and development expenses $202M (+32% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents, restricted cash and marketable securities · Q1-2026 | $3.90B | |
| Research and development expenses · Q1-2026 | $202M | +32% y/y |
Risks flagged
Clinical trial and regulatory risk; pipeline dependency.
“Multiple pipeline programs with binary outcomes; topline data readouts pending.”
Litigation dependency for future payments.
“Additional $1.3B contingent on Moderna Section 1498 appeal.”
6 Aug 202610-QRoivant reported Q1 FY2027 results with improved net loss, strong cash position boosted by $771.6M Moderna settlement, and continued pipeline progress.earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2027 | $3.84B | |
| Revenue · Q1-2027 | $1M | -34% y/y |
| Net loss attributable to Roivant Sciences Ltd. · Q1-2027 | $-190M | +15% y/y |
| Research and development expenses · Q1-2027 | $202M | +32% y/y |
| Cash and cash equivalents · Q1-2027 | $1.25B | |
| Operating cash flow · Q1-2027 | $-271M | -32% y/y |
| Free cash flow · Q1-2027 | $-271M | -30% y/y |
| Gain on litigation settlement · Q1-2027 | $392000.00 |
Risks flagged
Contingent Payment Uncertainty
“Moderna will make the Contingent Payment to Genevant/Arbutus (i) if the U.S. Court of Appeals for the Federal Circuit...affirms...the rejection of Moderna's affirmative defense...or (ii) upon a voluntary dismissal of Moderna's appeal.” · word for word
Clinical Trial and Regulatory Risk
“Clinical trials and preclinical studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes.” · word for word
Litigation Risk (Pfizer/BioNTech)
“We cannot predict the timing or outcome of these matters, and there is no assurance that the resolution of the Moderna Actions will be predictive of the outcome of the litigation against Pfizer and BioNTech.” · word for word
Operating Losses and Cash Burn
“The Company has incurred significant operating losses and negative cash flows from operations since its inception.” · word for word
29 Jul 2026DEF 14ARoivant Sciences filed its definitive proxy statement for the 2026 Annual General Meeting, disclosing strong Fiscal 2025 performance including $4.3B cash position, $2.25B Moderna settlement, 175% share price increase, and significant pipeliopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · FY2025 | $4.30B | |
| Net (loss) income · FY2025 | $-398M | |
| Share price · FY2025 | $27.70 | +175% y/y |
Risks flagged
Clinical trial failure risk
“Pipeline includes brepocitinib, IMVT-1402, and mosliciguat; all are in clinical development and subject to regulatory and clinical risks.”
Patent litigation risk
“Moderna settlement resolved one litigation, but Genevant/Arbutus lawsuit against Pfizer/BioNTech continues; claim construction ruling was favorable.”
Concentration of ownership
“Dexxon Holdings owns 14.2% of common shares; FMR LLC owns 10.2%; Morgan Stanley owns 6.8%; BlackRock owns 5.8%.”
20 May 20268-K · 2.02Cash, cash equivalents and marketable securities $4.30Bearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · March 31, 2026 | $4.30B |
Risks flagged
Clinical trial risk: IMVT-1402 data is open-label; further updates needed. Brepocitinib launch and Phase 3 data pending.
“Period 1 was conducted in an open-label setting; topline Phase 3 data for brepocitinib in NIU expected in H2 2026.” · word for word
2 Apr 20268-K · 2.02, 7.01Cash, cash equivalents and marketable securities $4.30B; Shares repurchased 3,956,362; Share repurchase amount $110Mearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and marketable securities · Q1-2026 | $4.30B | |
| Shares repurchased · Q1-2026 | 3,956,362 | |
| Share repurchase amount · Q1-2026 | $110M |
Risks flagged
Batoclimab Phase 3 TED studies failed primary endpoint, indicating pipeline risk.
“Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint” · word for word
3 Mar 20268-K · 1.01, 7.01, 8.01Roivant subsidiary Genevant and Arbutus reached a $2.25B global settlement with Moderna over LNP patent infringement. Moderna pays $950M upfront plus up to $1.3B contingent on appeal. Roivant also authorized $1B share repurchase (inclusiveopen
Figures in the filing · each found in the filing text
| Settlement amount · Q1-2026 | $2.25B | |
| Upfront payment · Q3-2026 | $950M | |
| Contingent payment · unknown | $1.30B | |
| Share repurchase authorization · Q1-2026 | $1.00B |
Risks flagged
Contingent payment dependent on appellate ruling introduces uncertainty.
“$1.3 billion contingent upon favorable resolution of Section 1498 appeal.”
3 Mar 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Regulatory approval not guaranteed; PDUFA date in Q3 2026 with potential for delay or rejection.
“FDA review ongoing; launch expected at end of September 2026 if approved.”
6 Feb 202610-QQuarterly results show widening net loss from continuing operations and declining revenue.earningsopen
Figures in the filing · each found in the filing text
| Net loss from continuing operations · 9M-2026 | $-754M | +58% y/y |
| Revenue · 9M-2026 | $6M | -73% y/y |
| Operating cash flow · 9M-2026 | $-587M | -12% y/y |
| Share-based compensation · 9M-2026 | $269M | +31% y/y |
| Accumulated deficit · Q3-2026 | $-695M |
Risks flagged
Significant operating losses and cash burn
“For the nine months ended December 31, 2025 and 2024, the Company incurred net losses from continuing operations of $753.7 million and $477.4 million, respectively.” · word for word
Dependence on future capital
“Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan.” · word for word
Revenue decline
“Revenue $5,740 thousand for nine months ended December 31, 2025 vs $21,483 thousand for nine months ended December 31, 2024.”
6 Feb 20268-K · 2.02Cash, cash equivalents, restricted cash and marketable securities $4.50Bearningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents, restricted cash and marketable securities · Q3-2026 | $4.50B |
Risks flagged
Litigation risk from LNP patent case; jury trial scheduled March 2026
“LNP litigation continues; jury trial in U.S. Moderna case scheduled for March 2026.”
10 Nov 202510-QRoivant Sciences reported a net loss from continuing operations of $439.95M for H1 FY2026, a significant increase from $268.44M in the prior year period, with cash burn of $390M.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q3-2026 | $1.24B | |
| Revenue · H1-2026 | $4M | -70% y/y |
| Net loss from continuing operations · H1-2026 | $-440M | |
| Research and development expense · H1-2026 | $317M | +21% y/y |
| Share-based compensation · H1-2026 | $164M | +35% y/y |
| Operating cash flow · H1-2026 | $-390M | |
| Free cash flow · H1-2026 | $-402M | |
| Accumulated deficit · Q3-2026 | $-429M |
Risks flagged
Cash burn and liquidity risk
“Net cash used in operating activities $390,047k for six months ended Sep 30, 2025; cash and cash equivalents decreased from $2,715,411k to $1,237,010k.”
Operating loss trajectory
“Loss from continuing operations, net of tax $439,950k for six months ended Sep 30, 2025 vs $268,444k for six months ended Sep 30, 2024.” · word for word
Revenue decline
“Revenue $3,741k for six months ended Sep 30, 2025 vs $12,465k for six months ended Sep 30, 2024.”
10 Nov 20258-K · 2.02Cash, cash equivalents, restricted cash and marketable securities $4.40B; Research and development expenses $165M (+15% y/y)earningsopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents, restricted cash and marketable securities · Q2-2026 | $4.40B | |
| Research and development expenses · Q2-2026 | $165M | +15% y/y |
Risks flagged
Litigation risk from LNP cases; jury trial scheduled for March 2026.
“Jury trial in U.S. Moderna case scheduled for March 2026” · word for word
Roivant Sciences Ltd. — questions
- What did Roivant Sciences Ltd. file recently?
- 20 SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Roivant announces positive Phase 3 CLARITY results for brepocitinib in non-infectious uveitis: met primary endpoint (time to treatment failure, p<0.0001) and all key secondary endpoints with high statistical significance. Median time to fai
Every figure on this page comes from Roivant Sciences Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.